Physician profile
Perry Tan
NPI 1669174470
$1,347.52
in general payments reported to CMS, 2019-2025
11 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $621 · 2024: $455 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $255.09 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kci USA, INC. | $152.82 | 2023 | Prevena, V.A.C. Dermatac, Abthera |
| Acera Surgical, INC. | $149.03 | 2023 | Restrata Wound Matrix |
| Bone Support INC. | $144.34 | 2025 | Ceramentbone Void Filler, Cerament G |
| Orthofix Medical, INC. | $131.57 | 2023 | Physio-Stim |
| Progenacare Global, LLC | $126.62 | 2024 | |
| Smith+Nephew, INC. | $126.26 | 2025 | Grafix Pl |
| Amgen INC. | $121.35 | 2024 | Krystexxa |
| Heron Therapeutics, INC. | $105.46 | 2024 | Zynrelef |
| Convatec INC. | $20.40 | 2023 | |
| Paragon 28, INC. | $14.58 | 2024 | Bun-Yo-Matic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.